2-(4-methoxy-2,5-dimethylphenyl)ethanamine | 52670-13-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-methoxy-2,5-dimethylphenyl)ethanamine
• 英文别名: 4-methoxy-2,5-dimethyl-phenethylamine；5-Methoxy-1.4-dimethyl-2-(β-amino-aethyl)-benzol；4-Methoxy-2.5-dimethyl-β-phenaethylamin；4-Methoxy-2,5-dimethyl-phenaethylamin；2-(4-Methoxy-2,5-dimethyl-phenyl)-ethylamine
• CAS: 52670-13-0
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: YZPKNWYCFSKKOK-UHFFFAOYSA-N

物化性质

• 沸点：
  120-122 °C(Press: 0.25 Torr)
• 密度：
  0.982±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-methoxy-2,5-dimethylphenyl)ethanamine 在 溶剂黄146 、 sodium nitrite 作用下， 生成 4-methoxy-2,5-dimethyl-phenethyl alcohol
  参考文献：
  名称：

  A patient with type I CD36 deficiency whose myocardium accumulated123I-BMIPP after 4 years

  摘要：

  A 73-year-old man with aortic regurgitation was examined by I-123-alpha -methyl-p-iodophenylpentadecanoic acid (BMIPP) myocardial single photon emission computed tomography (SPECT) in 1995. Myocardial accumulation was not evident on either the early or the delayed image obtained 15 minutes and 3 hours, respectively, after injecting I-123-BMIPP. Flow cytometric analysis of CD36 expression in monocytes and platelets identified a type I CD36 deficiency. The patient was hospitalized for severe heart failure in 1999. Upon admission, the cardiothoracic ratio on chest Xrays was 73%, and the left ventricular end-diastolic diameter on echocardiograms was enlarged to 77 mm. On the second day, we performed I-123-BMIPP myocardial SPECT. Myocardial accumulation was evident in the delayed, but not in the early image. We repeated I-123-BMIPP myocardial SPECT on the 10th day after admission. Myocardial accumulation was evident on both early and delayed images. Tc-99m-tetrofosmin myocardial SPECT was immediately performed after I-123-BMIPP myocardial SPECT to distinguish myocardial from pooling images in the left ventricle, but, because the images from both 99mTc-tetrofosmin and I-123-BMIPP myocardial SPECT were idential, we considered that the 123I-BMIPP myocardial SPECT images reflected the actual myocardial condition.The CD36 molecule transports long-chain fatty acid (LCFA) on the myocardial membrane, but I-123-BMIPP scintigraphy does not show any myocardial accumulation in patients with type I CD36 deficiency, indicating that myocardial LCFA uptake occurs through CD36 on the human myocardial membrane. Even though our patient had type I CD36 deficiency, BMIPP was uptaken by the myocardium during heart failure, suggesting a variant pathway on the human myocardial membrane for LCFA uptake.

  DOI：

  10.1007/bf02987845
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium hypochlorite 作用下， 生成 2-(4-methoxy-2,5-dimethylphenyl)ethanamine
  参考文献：
  名称：

  A patient with type I CD36 deficiency whose myocardium accumulated123I-BMIPP after 4 years

  摘要：

  A 73-year-old man with aortic regurgitation was examined by I-123-alpha -methyl-p-iodophenylpentadecanoic acid (BMIPP) myocardial single photon emission computed tomography (SPECT) in 1995. Myocardial accumulation was not evident on either the early or the delayed image obtained 15 minutes and 3 hours, respectively, after injecting I-123-BMIPP. Flow cytometric analysis of CD36 expression in monocytes and platelets identified a type I CD36 deficiency. The patient was hospitalized for severe heart failure in 1999. Upon admission, the cardiothoracic ratio on chest Xrays was 73%, and the left ventricular end-diastolic diameter on echocardiograms was enlarged to 77 mm. On the second day, we performed I-123-BMIPP myocardial SPECT. Myocardial accumulation was evident in the delayed, but not in the early image. We repeated I-123-BMIPP myocardial SPECT on the 10th day after admission. Myocardial accumulation was evident on both early and delayed images. Tc-99m-tetrofosmin myocardial SPECT was immediately performed after I-123-BMIPP myocardial SPECT to distinguish myocardial from pooling images in the left ventricle, but, because the images from both 99mTc-tetrofosmin and I-123-BMIPP myocardial SPECT were idential, we considered that the 123I-BMIPP myocardial SPECT images reflected the actual myocardial condition.The CD36 molecule transports long-chain fatty acid (LCFA) on the myocardial membrane, but I-123-BMIPP scintigraphy does not show any myocardial accumulation in patients with type I CD36 deficiency, indicating that myocardial LCFA uptake occurs through CD36 on the human myocardial membrane. Even though our patient had type I CD36 deficiency, BMIPP was uptaken by the myocardium during heart failure, suggesting a variant pathway on the human myocardial membrane for LCFA uptake.

  DOI：

  10.1007/bf02987845

文献信息

• [EN] TETRAHYDROISOQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TÉTRAHYDROISOQUINOLINE
  申请人：VIIV HEALTHCARE UK LTD

  公开号：WO2017093938A1

  公开（公告）日：2017-06-08

  Compounds of Formula (I) are disclosed and methods of treating viral infections with compositions comprising such compounds.

  化合物的化学式（I）已经公开，并且揭示了使用含有这些化合物的组合物治疗病毒感染的方法。
• PTERIDINES AND THEIR USE AS AGROCHEMICALS
  申请人：Brewster William K.

  公开号：US20110054173A1

  公开（公告）日：2011-03-03

  The present disclosure relates to 1- or 2-(4-(aryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and 1- or 2-(4-(heteroaryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and their use as agrochemicals and animal health products.

  本公开涉及1-或2-(4-(芳氧基)苯基)乙基氨基、氧基或硫基)喹啉和1-或2-(4-(杂芳氧基)苯基)乙基氨基、氧基或硫基)喹啉及其作为农药和动物健康产品的用途。
• [EN] PTERIDINES AND THEIR USE AS AGROCHEMICALS<br/>[FR] PTÉRIDINES ET LEUR UTILISATION COMME PRODUITS AGROCHIMIQUES
  申请人：DOW AGROSCIENCES LLC

  公开号：WO2011025505A1

  公开（公告）日：2011-03-03

  The present disclosure relates to 1- or 2-(4-(aryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and 1- or 2-(4-(heteroaryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and their use as agrochemicals and animal health products.

  本公开涉及1-或2-(4-(芳氧基)苯基)乙基氨基、氧基或硫基)喹啉和1-或2-(4-(杂芳氧基)苯基)乙基氨基、氧基或硫基)喹啉及其作为农药和动物保健产品的用途。
• Compounds useful for the treatment of diseases
  申请人：Brown Daniel Alan

  公开号：US20050234097A1

  公开（公告）日：2005-10-20

  The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  本发明涉及式（1）的化合物，以及用于制备这些化合物的中间体，含有这些化合物的组合物，以及这些衍生物的用途和应用。根据本发明的化合物在许多疾病、疾病和病情中非常有用，特别是在炎症、过敏和呼吸系统疾病、疾病和病情方面。
• THIAZOLO[5,4-d] PYRIMIDINES AND THEIR USE AS AGROCHEMICALS
  申请人：Brewster William K.

  公开号：US20110166164A1

  公开（公告）日：2011-07-07

  The present disclosure relates to thiazolo[5,4-d]pyrimidines and their use as agrochemicals and animal health products.

  本公开涉及噻唑并[5,4-d]嘧啶及其作为农药和动物保健产品的用途。